Scientists Advocate Multi‑Target Alzheimer’s Strategy
SkimNews Take
Treating Alzheimer's as a brain-localized amyloid problem produced modestly effective drugs; reframing it as a systemic aging condition raises the practical bar for designing trials that can test combinations across biology the existing single-target pipeline isn't built to evaluate.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Yan‑Jiang Wang and colleagues published a review in Science China Life Sciences arguing that single‑target Alzheimer’s treatments have fallen short because the disease involves multiple interconnected factors.
- lecanemab is mentioned as a monoclonal antibody that slows cognitive decline but does not reverse Alzheimer’s or restore normal brain function.
- donanemab is also noted as a monoclonal antibody with modest benefits, highlighting the limitation of single‑target therapies.
- CRISPR/Cas9 is highlighted as a potential one‑time gene‑editing therapy that could modify Alzheimer’s risk at its source.
- APOE ε4 is identified as the most widely recognized genetic risk factor, with researchers also finding additional population‑specific variants.
- plasma pTau217 is cited as an early biomarker that could enable precision‑medicine approaches to identify and treat Alzheimer’s earlier.
- Science China Life Sciences is the journal publishing the review that calls for integrated, multi‑target therapeutic strategies, including combined Aβ and Tau targeting, gut‑brain interventions, and advanced models like human iPSC‑derived organoids.
Why it matters: Patients stand to gain more effective treatments as researchers pivot to multi‑target strategies, while firms betting on single‑target monoclonal antibodies may see diminishing returns. The review’s call for integrated therapies could reshape drug pipelines and accelerate precision‑medicine adoption and shift funding toward interdisciplinary collaborations.
